Earnings ·
Pulmonx reports Q3 revenue of $22.8M and cuts net loss by 40% to $8.4M
LUNGPulmonx Corp
Pulmonx Corporation reported third-quarter 2026 worldwide revenue of $22.8 million, a 6% increase from the prior year period. U.S. sales rose 7% to $14.9 million, while international revenue grew 5% to $7.9 million, excluding China where commercial activity is restarting. Gross margin improved to 76%, and operating expenses decreased 18% to $24.9 million due to cost realignment efforts. The company posted a net loss of $8.4 million, or $0.19 per share, compared to a $14.0 million loss in the same period last year, representing a 40% reduction. Adjusted EBITDA loss narrowed by 57% to $3.5 million. Cash and cash equivalents stood at $52.7 million as of September 30, 2026. Pulmonx Corporation is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD).